Surrozen is a biotechnology company developing targeted therapeutics that harness Wnt signaling to address sight-threatening ophthalmic conditions.
For the full year 2025, Surrozen reported total revenue of $3.5 million, generated entirely from related-party research services. The company did not record any collaboration and license revenue during this period. The net loss per share (EPS) for the year stood at ($32.37).
The company concluded 2025 with a cash and cash equivalents position of $89.2 million. Annual research and development expenses amounted to $29.4 million , which contributed to a total net loss of $242.0 million for the year.